Voyageur Pharmaceuticals Ltd. announced the release of the white paper titled "SmoothX: A Promising New Positive Oral contrast Agent for CT."Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX, emphasising its potential to optimize abdominal CT examinations and maximize patient satisfaction. Oral contrast agents have long been vital in elevating diagnostic accuracy and effectiveness in medical imaging procedures. With the introduction of SmoothX, Voyageur is offering a positive oral contrast agent that not only enhances diagnostic outcomes but also provides a pleasant taste, enhancing patient satisfaction.

In a recent blinded study comparing SmoothX with the established oral contrast agent Readi- CAT2, Voyageur conducted a detailed evaluation, demonstrating that SmoothX exhibited nearly identical diagnostic imaging properties. This finding establishes SmoothX as a reliable alternative that maintains the uncompromising standards of image quality required for precise diagnosis. Of notable importance is the taste test study conducted alongside the clinical evaluation.

The results revealed a remarkable preference for the palatable flavor of SmoothX among the majority of the participants compared to Readi-CAT2. This preference for SmoothX's taste has the potential to translate into heightened patient satisfaction and increased compliance during abdominal CT examinations. Voyageur extends heartfelt appreciation to the dedicated team at Canada Diagnostic Centre in Calgary for their invaluable participation in this study.

Under the exceptional leadership of Jay Zelazo, MD, FRCPC, Director of CT, along with Jordan Muth, MRT (MR), MRI & CT Manager, and Michelle Holstein, Radiological Technologist, MRT (R) (MR), the study was meticulously executed, contributing significantly to the credibility and reliability of the findings. SmoothX represents a leap forward in oral contrast agents for CT imaging, aiming to provide a superior patient experience while ensuring optimal diagnostic outcomes. Voyageur remains steadfast in its commitment to continuous innovation, dedicated to improving the quality of care for patients worldwide.